source
- Merck briefly lists, then removes, phase 2 trial of PD-1xVEGF bispecific with TROP2 ADCMerck & Co. posted a clinical trial listing for a phase‑2 study combining its PD‑1xVEGF bispecific antibody (MK‑2010) with the TROP2‑directed antibody‑drug conjugate sac‑TMT. The listing, shown as…
- AI startup Doctronic acquires text-message pediatric care provider Summer HealthDoctronic, a startup that markets itself as an AI doctor, announced it has purchased Summer Health, a company that offers pediatric care via text messaging. The acquisition expands Doctronic’s ser…